Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study
Introduction: Reduction in bone mineral density (BMD) is a common side effect of androgen deprivation therapy (ADT). We aimed to examine the cross-sectional and longitudinal variation in BMD and associated bone markers in patients with nonmetastatic prostate cancer (PCa) managed with and without ADT...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-10-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.1177/1179554917733449 |
| _version_ | 1819093669751291904 |
|---|---|
| author | Alice Wang Nishi Karunasinghe Lindsay Plank Shuotun Zhu Sue Osborne Karen Bishop Charis Brown Tiffany Schwass Jonathan Masters Michael Holmes Roger Huang Christine Keven Lynnette Ferguson Ross Lawrenson |
| author_facet | Alice Wang Nishi Karunasinghe Lindsay Plank Shuotun Zhu Sue Osborne Karen Bishop Charis Brown Tiffany Schwass Jonathan Masters Michael Holmes Roger Huang Christine Keven Lynnette Ferguson Ross Lawrenson |
| author_sort | Alice Wang |
| collection | DOAJ |
| description | Introduction: Reduction in bone mineral density (BMD) is a common side effect of androgen deprivation therapy (ADT). We aimed to examine the cross-sectional and longitudinal variation in BMD and associated bone markers in patients with nonmetastatic prostate cancer (PCa) managed with and without ADT. Methods: Bone mineral density of the total body, lumbar spine, femoral neck, ultradistal forearm, and one-third distal radius was measured in 88 patients with PCa without bone metastases at baseline and at 6 months. Patients were categorized into 4 groups: (1) acute ADT (≤6 months), (2) chronic ADT (>6 months), (3) former ADT, and (4) no ADT (controls). Serum levels of bone metabolism markers, procollagen type I N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide of type I collagen (CTX), were also measured. Results: In the cross-sectional analysis, men receiving chronic ADT had significantly lower total body BMD as compared with former ADT users and men with no ADT. In longitudinal analysis, a significant reduction in ultradistal forearm BMD was observed in both acute and chronic ADT users after 6 months (4.08% and 2.7%, P = .012 and .026, respectively). A significant reduction in total body BMD was observed in acute ADT users (2.99%, P = .032). Former ADT users had a significant increase in both lumbar spine and femoral neck BMD (2.84% and 1.59%, P = .008 and .002, respectively). The changes in BMD were not significantly different between acute and chronic ADT users. In the cross-sectional analysis, higher levels of PINP and CTX were observed in acute and chronic ADT users than former ADT users or PCa controls. In longitudinal analysis, the level of serum PINP and CTX did not change significantly from baseline to 6 months in acute, chronic, and former ADT users, or PCa controls, and the percentage change did not differ among the 4 groups. Conclusions: Men on acute ADT had a similar rate of bone loss to men on chronic ADT. Reversibility in ADT-induced bone loss was observed in those who discontinued ADT. Serum levels of PINP and CTX were higher in acute and chronic ADT users and levels returned to the range of PCa controls when treatment was withdrawn. |
| first_indexed | 2024-12-21T23:15:11Z |
| format | Article |
| id | doaj.art-7e4cf81ad0a94171a672eb4e138665b4 |
| institution | Directory Open Access Journal |
| issn | 1179-5549 |
| language | English |
| last_indexed | 2024-12-21T23:15:11Z |
| publishDate | 2017-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Oncology |
| spelling | doaj.art-7e4cf81ad0a94171a672eb4e138665b42022-12-21T18:46:56ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492017-10-011110.1177/1179554917733449Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot StudyAlice Wang0Nishi Karunasinghe1Lindsay Plank2Shuotun Zhu3Sue Osborne4Karen Bishop5Charis Brown6Tiffany Schwass7Jonathan Masters8Michael Holmes9Roger Huang10Christine Keven11Lynnette Ferguson12Ross Lawrenson13Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New ZealandAuckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New ZealandDepartment of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New ZealandAuckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New ZealandUrology Department, North Shore Hospital, Auckland, New ZealandAuckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New ZealandNational Institute of Demographic and Economic Analysis, The University of Waikato, Hamilton, New ZealandUrology Department, Waikato Hospital, Hamilton, New ZealandUrology Department, Auckland Hospital, Auckland, New ZealandUrology Department, Waikato Hospital, Hamilton, New ZealandDepartment of Radiation Oncology, Waikato Hospital, Hamilton, New ZealandLiggins Institute, The University of Auckland, Auckland, New Zealand.Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New ZealandNational Institute of Demographic and Economic Analysis, The University of Waikato, Hamilton, New ZealandIntroduction: Reduction in bone mineral density (BMD) is a common side effect of androgen deprivation therapy (ADT). We aimed to examine the cross-sectional and longitudinal variation in BMD and associated bone markers in patients with nonmetastatic prostate cancer (PCa) managed with and without ADT. Methods: Bone mineral density of the total body, lumbar spine, femoral neck, ultradistal forearm, and one-third distal radius was measured in 88 patients with PCa without bone metastases at baseline and at 6 months. Patients were categorized into 4 groups: (1) acute ADT (≤6 months), (2) chronic ADT (>6 months), (3) former ADT, and (4) no ADT (controls). Serum levels of bone metabolism markers, procollagen type I N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide of type I collagen (CTX), were also measured. Results: In the cross-sectional analysis, men receiving chronic ADT had significantly lower total body BMD as compared with former ADT users and men with no ADT. In longitudinal analysis, a significant reduction in ultradistal forearm BMD was observed in both acute and chronic ADT users after 6 months (4.08% and 2.7%, P = .012 and .026, respectively). A significant reduction in total body BMD was observed in acute ADT users (2.99%, P = .032). Former ADT users had a significant increase in both lumbar spine and femoral neck BMD (2.84% and 1.59%, P = .008 and .002, respectively). The changes in BMD were not significantly different between acute and chronic ADT users. In the cross-sectional analysis, higher levels of PINP and CTX were observed in acute and chronic ADT users than former ADT users or PCa controls. In longitudinal analysis, the level of serum PINP and CTX did not change significantly from baseline to 6 months in acute, chronic, and former ADT users, or PCa controls, and the percentage change did not differ among the 4 groups. Conclusions: Men on acute ADT had a similar rate of bone loss to men on chronic ADT. Reversibility in ADT-induced bone loss was observed in those who discontinued ADT. Serum levels of PINP and CTX were higher in acute and chronic ADT users and levels returned to the range of PCa controls when treatment was withdrawn.https://doi.org/10.1177/1179554917733449 |
| spellingShingle | Alice Wang Nishi Karunasinghe Lindsay Plank Shuotun Zhu Sue Osborne Karen Bishop Charis Brown Tiffany Schwass Jonathan Masters Michael Holmes Roger Huang Christine Keven Lynnette Ferguson Ross Lawrenson Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study Clinical Medicine Insights: Oncology |
| title | Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study |
| title_full | Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study |
| title_fullStr | Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study |
| title_full_unstemmed | Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study |
| title_short | Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study |
| title_sort | effect of androgen deprivation therapy on bone mineral density in a prostate cancer cohort in new zealand a pilot study |
| url | https://doi.org/10.1177/1179554917733449 |
| work_keys_str_mv | AT alicewang effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT nishikarunasinghe effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT lindsayplank effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT shuotunzhu effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT sueosborne effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT karenbishop effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT charisbrown effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT tiffanyschwass effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT jonathanmasters effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT michaelholmes effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT rogerhuang effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT christinekeven effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT lynnetteferguson effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy AT rosslawrenson effectofandrogendeprivationtherapyonbonemineraldensityinaprostatecancercohortinnewzealandapilotstudy |